Clinical Trial Update: Safety and Tolerance Study of Oral Doses of CT53518 to Treat Patients With Acute Myelogenous Leukemia (AML) [Phase 1]

View source ↗

Summary

A Phase 1 safety and tolerance study of oral CT53518 in patients with acute myeloid leukemia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndrome

Drugs mentioned

• CT53518 (CT53518)

Snippet

Sponsor: Millennium Pharmaceuticals, Inc. | Conditions: Acute Myelogenous Leukemia, Myelodysplastic Syndrome | Phase 1 | Status: COMPLETED